Bensberg (OTS) - Girindus, with core competencies in process
development, scale up and manufacture of innovative drug and cosmetic
actives, sees a significant increase in demand for its commercial
oligonucleotide production capabilities in the USA and Europe.
"Our know-how and our technical expertise in the area of
oligonucleotide research, development and manufacturing has been
validated by an increased market demand. To respond to this demand we
have accelerated the expansion program of our US commercial cGMP
manufacturing facility located in Cincinnati Ohio", commented the CEO
Robert F. Link.
In addition to the solid phase production in Cincinnati Girindus
offers a unique solution phase process at its European facility which
is targeted towards the cost-efficient manufacture of large
commercial quantities.
Originaltext: Girindus AG digital press kits: http://presseportal.de/story.htx?firmaid=23521 press kits via RSS: feed://presseportal.de/rss/pm_23521.rss2 ISIN: DE0005880405
For further information, please contact:
Rückfragehinweis:
Peter J. Bergsteiner, Director Investor Relations Girindus AG, 51402 Bensberg T: +49 - (0)2204 - 926 - 900 F: +49 - (0)2204 - 926 - 990 pbergsteiner@girindus.com
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | EUN
